CY1114661T1 - Ταυτοποιηση αντιγονων που σχετιζονται με ογκο για διαγνωση και θεραπεια - Google Patents

Ταυτοποιηση αντιγονων που σχετιζονται με ογκο για διαγνωση και θεραπεια

Info

Publication number
CY1114661T1
CY1114661T1 CY20131101005T CY131101005T CY1114661T1 CY 1114661 T1 CY1114661 T1 CY 1114661T1 CY 20131101005 T CY20131101005 T CY 20131101005T CY 131101005 T CY131101005 T CY 131101005T CY 1114661 T1 CY1114661 T1 CY 1114661T1
Authority
CY
Cyprus
Prior art keywords
diagnosis
treatment
identification
volume
antigens related
Prior art date
Application number
CY20131101005T
Other languages
English (en)
Inventor
Ugur Sahin
Özlem Türeci
Michael Koslowski
Dirk Usener
Original Assignee
Ganymed Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganymed Pharmaceuticals Ag filed Critical Ganymed Pharmaceuticals Ag
Publication of CY1114661T1 publication Critical patent/CY1114661T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

Η εφεύρεση αναφέρεται σε γενετικά προϊόντα η έκφραση των οποίων σχετίζεται με καρκινικές νόσους. Η εφεύρεση αναφέρεται επίσης στη θεραπεία και στη διάγνωση νόσων στις οποίες τα γενετικά προϊόντα εκφράζονται ή εκφράζονται παθολογικά, συγκεκριμένα σε καρκινικές νόσους.
CY20131101005T 2005-09-12 2013-11-13 Ταυτοποιηση αντιγονων που σχετιζονται με ογκο για διαγνωση και θεραπεια CY1114661T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20050019786 EP1762575A1 (en) 2005-09-12 2005-09-12 Identification of tumor-associated antigens for diagnosis and therapy
EP06791878.9A EP1924600B1 (en) 2005-09-12 2006-09-06 Identification of tumor-associated antigens for diagnosis and therapy

Publications (1)

Publication Number Publication Date
CY1114661T1 true CY1114661T1 (el) 2016-10-05

Family

ID=35285406

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20131101005T CY1114661T1 (el) 2005-09-12 2013-11-13 Ταυτοποιηση αντιγονων που σχετιζονται με ογκο για διαγνωση και θεραπεια
CY20151100395T CY1116951T1 (el) 2005-09-12 2015-04-30 Αναγνωριση αντιγονων που σχετιζονται με ογκο για διαγνωση και θεραπεια
CY20181100344T CY1120096T1 (el) 2005-09-12 2018-03-27 Αναγνωριση αντιγονων που σχετιζονται με ογκο για διαγνωση και θεραπεια

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20151100395T CY1116951T1 (el) 2005-09-12 2015-04-30 Αναγνωριση αντιγονων που σχετιζονται με ογκο για διαγνωση και θεραπεια
CY20181100344T CY1120096T1 (el) 2005-09-12 2018-03-27 Αναγνωριση αντιγονων που σχετιζονται με ογκο για διαγνωση και θεραπεια

Country Status (21)

Country Link
US (5) US20090202530A1 (el)
EP (14) EP1762575A1 (el)
JP (5) JP6037593B2 (el)
KR (2) KR101359697B1 (el)
CN (1) CN101305020B (el)
AU (1) AU2006291717B2 (el)
BR (1) BRPI0616827A2 (el)
CA (2) CA2820201C (el)
CY (3) CY1114661T1 (el)
DK (3) DK1924600T3 (el)
ES (4) ES2434945T3 (el)
HK (3) HK1168608A1 (el)
HR (3) HRP20131047T1 (el)
HU (1) HUE037307T2 (el)
LT (1) LT2894162T (el)
PL (3) PL2433954T3 (el)
PT (3) PT2894162T (el)
RS (3) RS53988B1 (el)
RU (2) RU2485974C2 (el)
SI (3) SI2433954T1 (el)
WO (1) WO2007031222A2 (el)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
AU2013206613B2 (en) * 2005-09-12 2017-03-02 Biontech Ag Identification of tumor-associated antigens for diagnosis and therapy
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
EP1970384A1 (en) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
AU2016201637B2 (en) * 2007-10-23 2017-05-25 Biontech Ag Identification of tumor-associated markers for diagnosis and therapy
AU2015205868B2 (en) * 2008-09-16 2017-04-27 Ganymed Pharmaceuticals Ag Monoclonal antibodies for treatment of cancer
EP2166021A1 (en) * 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
BR112012030794B1 (pt) * 2010-06-04 2019-11-26 Inserm ( Institut National De La Santé Et De La Recherche Médicale) Novos compostos imunoadjuvantes e usos dos mesmos
NZ730355A (en) 2011-05-24 2022-10-28 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Individualized vaccines for cancer
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2014082729A1 (en) 2012-11-28 2014-06-05 Biontech Ag Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
SG11201606439VA (en) 2014-02-07 2016-09-29 Dong Wha Pharm Co Ltd Anticancer adjuvant composition containing rip3 expression promoter as active ingredient, method for screening for anticancer adjuvant enhancing sensitivity of anticancer drug by promoting rip3 expression, and method for monitoring sensitivity of anticancer drug
WO2016040682A1 (en) 2014-09-10 2016-03-17 Genentech, Inc. Immunogenic mutant peptide screening platform
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
RU2620306C2 (ru) * 2015-01-15 2017-05-24 Олег Викторович Бухтояров Способ прогнозирования рецидива злокачественного опухолевого заболевания
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2016146618A1 (en) * 2015-03-16 2016-09-22 Max-Delbrück-Centrum für Molekulare Medizin Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors by means of an mhc cell library
CA2989373A1 (en) * 2015-06-16 2016-12-22 Targovax Asa Mutated fragments of the ras protein
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
SG11201804957VA (en) 2015-12-16 2018-07-30 Gritstone Oncology Inc Neoantigen identification, manufacture, and use
EP3400004A1 (en) 2016-01-08 2018-11-14 Vaccibody AS Therapeutic anticancer neoepitope vaccine
US10712310B2 (en) 2016-01-22 2020-07-14 Temple University—Of the Commonwealth System of Higher Education Protein quantification by near infrared spectral imaging
CN107266552B (zh) * 2016-03-30 2022-02-08 香雪生命科学技术（广东）有限公司 源自于prame的肿瘤抗原短肽
JP6717982B2 (ja) 2016-05-20 2020-07-08 アランセオ・ネザーランズ・ベー・フェー ゴム組成物
DE102016115246C5 (de) * 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
CN108250289B (zh) * 2016-12-28 2021-10-08 香雪生命科学技术（广东）有限公司 源自于mage b6的肿瘤抗原短肽
TWI676483B (zh) * 2017-08-06 2019-11-11 強普生技股份有限公司 醫藥套組及其用途
JP7227237B2 (ja) 2017-10-10 2023-02-21 グリットストーン バイオ インコーポレイテッド ホットスポットを利用した新生抗原の特定
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
JP7082556B2 (ja) 2018-09-28 2022-06-08 三和シヤッター工業株式会社 シャッター装置

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) * 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) * 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) * 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) * 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) * 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) * 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) * 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
JP3101690B2 (ja) * 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5013653A (en) * 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
AU612370B2 (en) * 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US4941880A (en) * 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) * 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) * 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) * 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
ATE196606T1 (de) * 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
US5744585A (en) * 1995-03-16 1998-04-28 Medenica; Rajko D. Human monoclonal antibody against lung carcinoma
US6121022A (en) * 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US20020065394A1 (en) * 1998-03-18 2002-05-30 Kenneth Jacobs Secreted proteins and polynucleotides encoding them
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9826143D0 (en) 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
MXPA01007148A (es) * 1999-01-13 2002-03-27 Igeneon Krebs Immuntherapie Uso de anticuerpos para vacunacion anti-cancer.
US6943235B1 (en) * 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
US6974667B2 (en) * 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
AU2001280608A1 (en) * 2000-07-18 2002-01-30 Curagen Corporation Human polynucleotides and polypeptides encoded thereby
IL154751A0 (en) * 2000-08-03 2003-10-31 Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
EP1916303B1 (en) 2000-11-30 2013-02-27 Medarex, Inc. Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice
US20020177547A1 (en) * 2001-01-16 2002-11-28 Karin Molling Pharmaceutical compositions for treating or preventing cancer
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2002097035A2 (en) * 2001-05-25 2002-12-05 Incyte Genomics, Inc. Secreted proteins
CA2457819A1 (en) * 2001-08-14 2003-02-27 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
WO2003075014A2 (en) * 2002-03-06 2003-09-12 Oxford Glycosciences (Uk) Ltd Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
WO2003102159A2 (en) * 2002-06-04 2003-12-11 Curagen Corporation Novel proteins and nucleic acids encoding same
US7053201B2 (en) * 2002-08-30 2006-05-30 National Defense Medical Center Nucleic acid molecules and polypeptides related to h-ADAM7
TW200418988A (en) * 2002-09-30 2004-10-01 Oncotherapy Science Inc Method for diagnosing prostate cancer
PL218660B1 (pl) 2002-10-17 2015-01-30 Genmab As Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
AU2003291399A1 (en) * 2002-11-06 2004-06-03 Sequenom, Inc. Methods for identifying risk of melanoma and treatments thereof
JP4624977B2 (ja) * 2003-01-17 2011-02-02 ザ チャイニーズ ユニバーシティ オブ ホンコン 妊娠障害診断マーカーとしての血中ｍＲＮＡ
AU2004210986A1 (en) * 2003-02-11 2004-08-26 Wyeth Methods for monitoring drug activities in vivo
WO2005049806A2 (en) * 2003-03-14 2005-06-02 Nuvelo, Inc. Novel nucleic acids and polypeptides
US20050255114A1 (en) * 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
RU2256924C2 (ru) * 2003-09-03 2005-07-20 Торопова Надежда Ефимовна Способ дифференциальной диагностики злокачественных опухолей простаты
WO2005079490A2 (en) * 2004-02-13 2005-09-01 Nuvelo, Inc. Methods of therapy and diagnosis using targeting of cells that express steap2 polypeptides
CN1663603A (zh) * 2004-03-02 2005-09-07 北京大学 一种肿瘤－胎盘抗原蛋白及其dna在肿瘤治疗中的应用
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1970384A1 (en) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
CN107028969A (zh) * 2009-02-20 2017-08-11 加尼梅德药物公司 用于癌症诊断和治疗的方法和组合物
EP2221063A1 (en) * 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer

Also Published As

Publication number Publication date
US20110189179A1 (en) 2011-08-04
RS57080B1 (sr) 2018-06-29
CA2820201C (en) 2018-07-17
JP5913547B2 (ja) 2016-04-27
US9919036B2 (en) 2018-03-20
EP2902412A1 (en) 2015-08-05
EP2433955A2 (en) 2012-03-28
WO2007031222A3 (en) 2007-07-26
RU2013113439A (ru) 2014-10-10
EP2433962A2 (en) 2012-03-28
US8975375B2 (en) 2015-03-10
EP2433954B8 (en) 2015-05-13
HK1211606A1 (en) 2016-05-27
HRP20131047T1 (hr) 2013-12-06
AU2006291717B2 (en) 2013-06-06
PT2894162T (pt) 2018-04-02
RS53009B (en) 2014-04-30
EP2433955A3 (en) 2012-07-04
HK1118840A1 (en) 2009-02-20
EP2433962A3 (en) 2012-07-04
JP6037593B2 (ja) 2016-12-07
EP2433959A3 (en) 2012-06-27
CA2620712A1 (en) 2007-03-22
LT2894162T (lt) 2018-04-10
DK2894162T3 (en) 2018-04-16
ES2532410T3 (es) 2015-03-26
EP1762575A1 (en) 2007-03-14
CY1116951T1 (el) 2017-04-05
EP2902412B1 (en) 2018-02-21
EP2433958A2 (en) 2012-03-28
EP2433960B1 (en) 2015-03-04
JP6196338B2 (ja) 2017-09-13
CY1120096T1 (el) 2018-12-12
BRPI0616827A2 (pt) 2011-07-05
EP2433954B1 (en) 2015-02-25
US20170080068A1 (en) 2017-03-23
DK1924600T3 (da) 2013-11-11
HRP20180507T1 (hr) 2018-05-04
SI1924600T1 (sl) 2013-12-31
CA2820201A1 (en) 2007-03-22
PT2433954E (pt) 2015-06-02
ES2664386T3 (es) 2018-04-19
PL2433954T3 (pl) 2015-07-31
KR20130121198A (ko) 2013-11-05
EP1924600A2 (en) 2008-05-28
AU2006291717A1 (en) 2007-03-22
DK2433954T3 (en) 2015-05-04
RU2485974C2 (ru) 2013-06-27
JP2015120691A (ja) 2015-07-02
EP2433958A3 (en) 2012-07-04
SI2894162T1 (en) 2018-05-31
EP2433957A3 (en) 2012-07-04
JP2016166175A (ja) 2016-09-15
EP2894162B1 (en) 2018-01-03
PL2894162T3 (pl) 2018-06-29
EP2966082A1 (en) 2016-01-13
KR20080052664A (ko) 2008-06-11
JP2009507868A (ja) 2009-02-26
EP2433954A2 (en) 2012-03-28
CN101305020A (zh) 2008-11-12
EP2433960A2 (en) 2012-03-28
EP2433956A3 (en) 2012-07-04
EP2433956A2 (en) 2012-03-28
HK1168608A1 (en) 2013-01-04
US20140017254A1 (en) 2014-01-16
EP2894162A1 (en) 2015-07-15
RS53988B1 (en) 2015-10-30
KR101359697B1 (ko) 2014-02-07
EP2433958B1 (en) 2015-02-25
HUE037307T2 (hu) 2018-08-28
ES2535500T3 (es) 2015-05-12
EP2433962B1 (en) 2015-03-25
EP2433959A2 (en) 2012-03-28
US20090202530A1 (en) 2009-08-13
SI2433954T1 (sl) 2015-06-30
EP2433961A3 (en) 2012-06-27
ES2434945T3 (es) 2013-12-18
RU2008114318A (ru) 2009-10-20
PL1924600T3 (pl) 2014-01-31
CN101305020B (zh) 2015-09-02
EP1924600B1 (en) 2013-08-28
PT1924600E (pt) 2013-11-18
EP2433961A2 (en) 2012-03-28
US20150197576A1 (en) 2015-07-16
HRP20150432T1 (hr) 2015-09-25
RU2644686C2 (ru) 2018-02-13
WO2007031222A2 (en) 2007-03-22
EP2433957A2 (en) 2012-03-28
JP2013136579A (ja) 2013-07-11
EP2433960A3 (en) 2012-07-04
EP2433954A3 (en) 2012-07-04
EP2966082B1 (en) 2017-08-30
JP2016102116A (ja) 2016-06-02
JP5750433B2 (ja) 2015-07-22

Similar Documents

Publication Publication Date Title
CY1120096T1 (el) Αναγνωριση αντιγονων που σχετιζονται με ογκο για διαγνωση και θεραπεια
CY1123010T1 (el) Διεγερση γονιδιου τrail με μικρο μοριο απο κανονικα και ογκου κυτταρα ως αντικαρκινικη θεραπεια
CY1118369T1 (el) Αντισωματα εναντι cd38 για την θεραπεια πολλαπλου μυελωματος
CY1119209T1 (el) Αναστολεις κινασης τυροσινης bruton
CY1119219T1 (el) Anti-ceacam5 αντισωματα και χρησεις αυτων
CY1119123T1 (el) Δις-αρυλοσυζευγμενες αρυλοτριαζολονες και η χρηση τους
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
CY1116886T1 (el) C-met αντισωματα
CY1124412T1 (el) Aνti-dkk-1 αντισωματα
EA201700181A1 (ru) Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
DE602007013252D1 (de) Azyklische amininhibitoren von nukleosidphosphorylasen und hydrolasen
CY1112383T1 (el) Αναστολεις της πρωτεϊνης ενεργοποιησης της 5-λιποξυγενασης (flap)
EA201991763A1 (ru) Конъюгаты антитела к ccr7 и лекарственного средства
CY1112798T1 (el) Ενωσεις διαρυλυδαντοϊνης
CY1116823T1 (el) Στοχευση abcb5 για θεραπεια καρκινου
EA201000644A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
CY1119890T1 (el) Θεραπευτικη αγωγη ογκων χρησιμοποιωντας ειδικο αντισωμα αντι-l1
CY1120436T1 (el) Αντιανδρογονα πεπτιδια και χρησεις αυτων στη θεραπεια του καρκινου
CY1120084T1 (el) Oλiγονουκλεοτiδiα για τη ρυθμιση της γονιδιακης εκφρασης και οι χρησεις αυτων
CY1123926T1 (el) Αντισωματα κατα της τρανσγλουταμινασης 2
CY1116802T1 (el) Ετεροκυκλικες ενωσεις
CY1117579T1 (el) Παραγωγα φαινυλιου-γουανiδiνης
CY1117577T1 (el) Υποκατεστημενα φουρανοκαρβοξαμιδια και χρηση αυτων
CY1120255T1 (el) Αντισωμα αντι-β7-η3
CY1113725T1 (el) Μονοκλωνα αντισωματα τα οποια δεσμευονται σε hgm-csf και φαρμακευτικες συνθεσεις οι οποιες τα περιεχουν